Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Visen Pharma Completes Phase III Trial of Therapy for Rare Thyroid Disease

publication date: Jan 12, 2023

Shanghai Visen Pharma completed a Phase III trial of its novel therapy that restores parathyroid hormone in patients with hypoparathyroidism (HP), a rare disease. The trial tested palopegteriparatide, a prodrug, in a double-blind, multi-center China trial. The company said HP is the only remaining endocrine deficiency condition that does not have a hormone replacement as standard treatment. Visen acquired rights to the drug from Copenhagen’s Ascendis Pharma, which formed Visen as a 50-50 JV with a syndicate of China VCs in 2018. Visen will now analyze the results of the Phase III trial. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital